Automated surveillance to detect postprocedure safety signals of approved cardiovascular devices

JAMA

Volumn 304, Issue 18, 2010, Pages 2019-2027

  Resnic, Frederic S ^a   Gross, Thomas P ^b   Marinac Dabic, Danica ^b   Loyo Berrios, Nilsa ^b   Donnelly, Sharon ^a   Normand, Sharon Lise T ^a   Matheny, Michael E ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b CENTER FOR DEVICES AND RADIOLOGICAL HEALTH   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; AUTOMATION; BARE METAL STENT; CARDIOVASCULAR SURGERY; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; DEVICE; DRUG ELUTING STENT; FEMALE; HEART INFARCTION; HUMAN; IMPLANT; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; REGISTER; RISK ASSESSMENT; RISK FACTOR; SAFETY; SENSITIVITY ANALYSIS; SURGICAL TECHNIQUE;

EID: 78149345321     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2010.1633     Document Type: Article

References (34)

1. Gross TP, Kessler LG. Medical device vigilance at FDA. Stud Health Technol Inform. 1996;28:17-24.
2. Samore MH, Evans RS, Lassen A, et al. Surveillance of medical device-related hazards and adverse events in hospitalized patients. JAMA. 2004;291(3):325-334. (Pubitemid 38101605)
3. Maisel WH. Unanswered questions - drug-eluting stents and the risk of late thrombosis. N Engl J Med. 2007;356(10):981-984. (Pubitemid 46376797)
4. Shah JS, Maisel WH. Recalls and safety alerts affecting automated external defibrillators. JAMA. 2006;296(6):655-660.
5. Rosen CJ. The rosiglitazone story - lessons from an FDA Advisory Committee meeting. N Engl J Med. 2007;357(9):844-846.
6. Garber AM. Modernizing device regulation. N Engl J Med. 2010;362(13):1161-1163.
7. Platt R, Wilson M, Chan KA, Benner JS, Marchibroda J, McClellan M. The new Sentinel Network - improving the evidence of medical-product safety. N Engl J Med. 2009;361(7):645-647.
8. Holman WL, Pae WE, Teutenberg JJ, et al. INTERMACS: interval analysis of registry data. J Am Coll Surg. 2009;208(5):755-762.
9. Brindis RG, Fitzgerald S, Anderson HV, Shaw RE, Weintraub WS, Williams JF. The American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR): building a national clinical data repository. J Am Coll Cardiol. 2001;37(8):2240-2245.
10. Aggarwal A, Wang Y, Rumsfeld JS, Curtis JP, Heidenreich PA; National Cardiovascular Data Registry. Clinical characteristics and in-hospital outcome of patients with end-stage renal disease on dialysis referred for implantable cardioverter-defibrillator implantation. Heart Rhythm. 2009;6(11):1565-1571.
11. Hammill S, Phurrough S, Brindis R. The National ICD Registry: now and into the future. Heart Rhythm. 2006;3(4):470-473.
12. Matheny ME, Arora N, Ohno-Machado L, Resnic FS. Rare adverse event monitoring of medical devices with the use of an automated surveillance tool. AMIA Annu Symp Proc. 2007:518-522.
13. Mauri L, Silbaugh TS, Wolf RE, et al. Long-term clinical outcomes after drug-eluting and bare-metal stenting in Massachusetts. Circulation. 2008;118(18):1817-1827.
14. Percutaeous coronary intervention in the Commonwealth of Massachusetts: fiscal year 2007 report, October 1, 2006-September 30, 2007. Massachusetts Data Analysis Center Web site. http://www.massdac.org/sites/default/files/reports/ PCI%20FY2007.pdf. 2009. Accessed January 19, 2010.
15. Mauri L, Silbaugh TS, Garg P, et al. Drug-eluting or bare-metal stents for acute myocardial infarction. N Engl J Med. 2008;359(13):1330-1342.
16. Description of NCDR CathPCI Registry. National Cardiovascular Data Registry Web site. https://www.ncdr.com/webncdr/DefaultCathPCI.aspx. 2010. Accessed January 4, 2010.
17. Resnic FS, Zou KH, Do DV, Apostolakis G, Ohno-Machado L. Exploration of a Bayesian updating methodology to monitor the safety of interventional cardiovascular procedures. Med Decis Making. 2004;24(4):399-407. (Pubitemid 38955765)
18. Matheny ME, Morrow DA, Ohno-Machado L, Cannon CP, Sabatine MS, Resnic FS. Validation of an automated safety surveillance system with prospective, randomized trial data. Med Decis Making. 2009;29(2):247-256.
19. Matheny ME, Ohno-Machado L, Resnic FS. Risk-adjusted sequential probability ratio test control chart methods for monitoring operator and institutional mortality rates in interventional cardiology. Am Heart J. 2008;155(1):114-120. (Pubitemid 350234774)
20. Matheny ME, Ohno-Machado L, Resnic FS. Monitoring device safety in interventional cardiology. J Am Med Inform Assoc. 2006;13(2):180-187.
21. Austin PC. Some methods of propensity-score matching had superior performance to others: results of an empirical investigation and Monte Carlo simulations. Biom J. 2009;51(1):171-184.
22. Austin PC. The relative ability of different propensity score methods to balance measured covariates between treated and untreated subjects in observational studies. Med Decis Making. 2009;29(6):661-677.
23. Stone GW, Ellis SG, Cannon L, et al . Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease. JAMA. 2005;294(10):1215-1223.
24. Popma JJ, Mauri L, O'Shaughnessy C, et al. Frequency and clinical consequences associated with sidebranch occlusion during stent implantation using zotarolimus-eluting and paclitaxel-eluting coronary stents. Circ Cardiovasc Interv. 2009;2(2):133-139.
25. Nikolsky E, Mehran R, Halkin A, et al. Vascular complications associated with arteriotomy closure devices in patients undergoing percutaneous coronary procedures: a meta-analysis. J Am Coll Cardiol. 2004;44(6):1200-1209.
26. Koreny M, Riedmüller E, Nikfardjam M, Siostrzonek P, Müllner M. Arterial puncture closing devices compared with standard manual compression after cardiac catheterization. JAMA. 2004;291(3):350-357.
27. Tavris DR, Dey S, Albrecht-Gallauresi B, et al. Risk of local adverse events following cardiac catheterization by hemostasis device use - phase II. J Invasive Cardiol. 2005;17(12):644-650.
28. Warren BS, Warren SG, Miller SD. Predictors of complications and learning curve using the Angio-Seal closure device following interventional and diagnostic catheterization. Catheter Cardiovasc Interv. 1999;48(2):162-166.
29. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention. JAMA. 2003;289(7):853-863. (Pubitemid 37430344)
30. Stone GW, Ware JH, Bertrand ME, et al. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management. JAMA. 2007;298(21):2497-2506.
31. O'Shea JC, Kramer JM, Califf RM, Peterson ED. Identifying holes in the safety net. Am Heart J. 2004;147(6):977-984.
32. Peterson ED, Hirshfeld JW Jr, Ferguson TB, Kramer JM, Califf RM, Kessler LG. Sealing holes in the safety net. Am Heart J. 2004;147(6):985-990.
33. Rao SV, Califf RM, Kramer JM, et al. Postmarket evaluation of breakthrough technologies. Am Heart J. 2008;156(2):201-208.
34. FDA's Sentinel Initiative. US Food and Drug Administration Web site. http://www.fda.gov/Safety/FDAsSentinelInitiative/default.htm. 2010. Accessed May 3, 2010.